Two semaglutide papers this week reinforce a shift from “weight-loss drug” to “systems-impact therapy.” In an exploratory SELECT analysis (obesity/overweight + established CVD, no diabetes), semaglutide was associated with fewer total admissions and fewer days in hospital vs placebo—suggesting benefit shows up not just in event curves, but in real resource utilization and patient time at home. [1]
In adults with type 1 diabetes, obesity, and automated insulin delivery, a post hoc analysis reported clinically meaningful insulin dose reductions with semaglutide—useful for anticipating dose adjustments and safety monitoring when layering GLP-1 therapy onto closed-loop workflows. [2]
Practical “tactics” to consider now:
-
Build a proactive insulin-reduction playbook when starting GLP-1s in AID users (dose changes, hypoglycemia surveillance, ketone-risk counseling).
-
Use utilization outcomes in shared decision-making for obesity + CVD: fewer admissions/days can be meaningful to patients even when they’re not thinking in “MACE endpoints.”
-
Operationalize monitoring (GI intolerance, dehydration risk, sick-day rules) because the workflow burden shifts to front-loaded follow-up.
References
-
Nicholls SJ, Ryan DH, Deanfield J, et al; SELECT Trial Investigators. Semaglutide and hospitalizations in patients with obesity and established cardiovascular disease: an exploratory analysis of the SELECT randomized clinical trial. JAMA Cardiol. 2025;:e254824. https://doi.org/10.1001/jamacardio.2025.4824
PubMed: https://pubmed.ncbi.nlm.nih.gov/41433034/ PubMed -
Karakus KE, Akturk HK, Kruger D, et al. Effect of semaglutide on insulin dose reduction in adults with type 1 diabetes and obesity using automated insulin delivery systems: ADJUST-T1D post hoc analysis. Diabetes Care. 2025;:dc252249. https://doi.org/10.2337/dc25-2249
PubMed: https://pubmed.ncbi.nlm.nih.gov/41429002/ PubMed